Novo Nordisk cagrilintide record moves to active, not recruiting

The Phase 3 entry covering adults living with overweight or obesity and type 2 diabetes was last updated on 7 October 2026.

Bethesda, Maryland, 7 October 2026 — The ClinicalTrials.gov registry record with identifier NCT07220759, a Phase 3 interventional study sponsored by Novo Nordisk A/S, was last updated on 7 October 2026 and carries the overall status active, not recruiting.

The registry returned 44 records in total for the search term cagrilintide on the day this wire was pulled.

Source documents

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide Trial registry record, Phase 3 · Novo Nordisk A/S · 7 October 2026
Identifier
Registry identifier NCT07220759
Registry status
ACTIVE_NOT_RECRUITING
Phase
PHASE3
Study type
INTERVENTIONAL
Last update posted
2026-10-07